Published guidance, NICE advice and quality standards | Guidance

Showing 111 to 120 of 330

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)	TA797	15 June 2022	15 June 2022
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations	TA789	18 May 2022	18 May 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy	TA788	11 May 2022	11 May 2022
Bladder EpiCheck for detecting bladder cancer recurrence	MIB293	3 May 2022	3 May 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies	TA786	27 April 2022	27 April 2022
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	TA784	20 April 2022	20 April 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	TA781	30 March 2022	30 March 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	TA779	16 March 2022	16 March 2022
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules	HTG611	23 February 2022	23 February 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	TA770	9 February 2022	9 February 2022